Tumor vasculature as target for therapeutic intervention
Authors:
- Gert StormGSGert Storm
- Raymond M SchiffelersRSRaymond M Schiffelers
- 15 October 2010
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 19 (11) , 1321-1338
Abstract
Importance of the field: Solid tumors rely on efficient oxygen and nutrients transport for their growth, development and survival. Many tumors can stimulate new blood vessel formation. Because this angiogenic vasculature is aberrant from normal host vasculature, several strategies have been explored that specifically target tumor blood vessels. Areas covered in this review: Over the past decade, many molecules that act on tumor vasculature have been identified. They can be divided into three groups based on their mechanism of action: i) antiangiogenic molecules cause tumor growth arrest; ii) vasoactive agents induce hyperabnormalization of the tumor vasculature, improving conventional drug accumulation in the tumor; iii) vascular disrupting agents that cause blood vessel congestion, resulting in massive secondary tumor cell necrosis. Many investigational drugs from these classes are currently being evaluated to assess their role in tumor therapy. What the reader will gain: The underlying principle of each...Keywords
This publication has 165 references indexed in Scilit:
- Cancer-related inflammationNature, 2008
- Isolated Limb Perfusion with Melphalan and TNF-α in the Treatment of Extremity SarcomaCurrent Treatment Options in Oncology, 2007
- Tumour vascularization: sprouting angiogenesis and beyondCancer and Metastasis Reviews, 2007
- VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospectsTrends in Molecular Medicine, 2007
- Genes that Distinguish Physiological and Pathological AngiogenesisCancer Cell, 2007
- Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancerNature Clinical Practice Oncology, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Angiogenesis in life, disease and medicineNature, 2005
- The biology of VEGF and its receptorsNature Medicine, 2003
- Extensive Vasculogenesis, Angiogenesis, and Organogenesis Precede Lethality in Mice Lacking All αv IntegrinsCell, 1998